Johnson & Johnson Reports 91% Net Profit Surge Amid Strategic Shift to Digital Health and High-Growth MedTech

▲ Source of the article: Eshare Medical Device Hub

▲Please indicate the above source at the beginning of the article when reprinting.

In the pharmaceutical and medical fieldIn the increasingly competitive 2025, Johnson & Johnson delivered an excellent quarterly performance.

In the latest third-quarter earnings report, it not only reflects the steady growth of its core business but also reveals that this hundred-year-old company...Year EnterpriseAccelerating the process of transforming from a traditional medical giant to an intelligent and digital medical technology company.

In the third quarter of 2025, Johnson & Johnson achievedTotal Revenue: $23.993 Billion, higher than the market expectation of 23.7 billion US dollars, increased year-on-year6.8%, with a month-on-month growth of approximately2.4%。

Among which, the revenue from the U.S. market was approximately$12.2 billion, an increase of 6.2% year-on-year; international market revenue was approximately$11.7 billion, an increase of 7.6% year-on-year, or 4.4% on a currency-neutral basis.

Net Profit (GAAP) was $5.152 billion，An increase of more than 2.694 billion US dollars compared to the same period last year91%, reflecting the significant achievements of the company in cost control, tax optimization, and the increase in the proportion of high-margin businesses.

Adjusted net profit was US$6.801 billion, Adjusted Earnings Per Share (EPS)$2.80, up 15.7% year-on-year, slightly higher than the analysts' consensus expectation of $2.74.

Gross profit margin remains atApproximately 68%High level,Operating profit margin increased from 19.5% in the same period last year to22.4%。

Operating cash flow is approximately$14.2 billion, an increase of more than 12% year-on-year, with free cash flow at$9.3 billion, with total cash reserves exceeding$27 billionThis provides Johnson & Johnson with strong ammunition for future mergers and acquisitions and capital return plans.

After the earnings report was released, the management raised the full-year revenue guidance toUSD 93.5-93.9 billion, the adjusted EPS target for the year in China has been raised to$10.85This indicates that, driven by multi-line growth, the company expects its future profitability momentum to continue strengthening.

Johnson & Johnson's current business is composed of two core segments: Innovative Medicine and MedTech, which together serve as the dual engines driving the company's growth.

Innovative Pharmaceutical BusinessRevenue for this quarter was approximately$15.56 billion, an increase of 6.8% year-on-year.

The oncology treatment product line remains the main growth driver.Among themDarzalex (Daratumumab)Sales increased by 22% year-on-year, driving the entire oncology sector's revenue to exceed 2 billion US dollars.

In the Field of ImmunologyTremfyaandSimponiPerformance is stable, partially offsettingStelaraThe pressure brought by patent expiration.

Neuroscience and rare disease pharmaceuticals also achieved mid-single-digit growth, laying the foundation for future pipeline development.

Medical Technology BusinessRevenue is$8.43 billion, a year-on-year increase of 5.6% and a month-on-month increase of 1.7%, performing better than the average level in the overall medical device industry.

Among them,Cardiovascular TechnologyThe business achieved double-digit growth after acquiring Abiomed and Shockwave Medical. The surgical instruments, wound closure, and vision care product lines maintained robust growth, driving the segment to achieve positive growth for the seventh consecutive quarter.

Executive Vice President and Global Chairman of Johnson & Johnson Medical TechnologyTim Schmid pointed out in the interview that the improvement in profitability of this segment also comes from product mix optimization and the increase in gross profit margin of digital surgical equipment.

From a regional perspective, North America and Europe contributed to the main growth, while the significant rebound in surgical equipment sales in the Asian market, especially in China, has become an important engine driving international revenue.

At the same time as the earnings report was released, Johnson & Johnson announced that it wouldPeeling off its long historyOrthopedics，And let it beDePuy SynthesNominal independent operation is expected to be completed within the next 24 months.

The business is expected to generate approximately $9.2 billion in revenue in 2024, accounting for about 10% of the company's total income, but its growth rate has slowed in recent years, remaining at around 2%.

By divesting, Johnson & Johnson hopes to focus its resources on higher-growth areas such as cardiovascular, digital surgery, and AI-driven medical imaging.

Tim Schmid stated that this adjustment is not only a financial decision but also a natural extension of strategic transformation:

"We have been shifting our investment portfolio from low-growth markets to high-growth markets over the past few years. This divestiture allows us to allocate resources more precisely and lay the foundation for innovation in the next decade."

From a financial perspective, the spin-off will help improve the overall profit margin. According to Johnson & Johnson's estimates,After the split, the operating profit margin of the group is expected to increase by approximately70 to 100 basis points, the cash return rate and asset turnover efficiency will also improve significantly.

In the medical technology sector, the surgical robotics business is becoming a long-term growth driver for Johnson & Johnson.

The financial report shows that J&J MedTech's revenue from robotic surgery and intelligent navigation devices increased by approximately [percentage]% year-over-year this quarter.12%, contributing one-third of the segment's incremental revenue.

Johnson & Johnson currently has two core platforms:

Monarch System: Mainly used for the early diagnosis of lung cancer, precise localization of lesions through robotic bronchoscopy to achieve biopsies with a higher success rate. In 2025, Monarch received FDA approval for its upgraded version.Monarch QuestWith the approval, the new system introduces AI navigation and high-resolution imaging technology, which can reduce doctors' operational errors by more than 20%. The company expects that Monarch Quest will enter the urology market in 2026 for kidney stone treatment and early screening of urinary tumors.

Ottava System：As the core platform of Johnson & Johnson's digital surgery strategy, Ottava is expected to complete its first clinical applications in 2025, with formal regulatory submission projected for 2026. The system’s four-arm structure is directly integrated into the electric operating table, saving 30% of operating room space and improving procedural efficiency.
The company plans to integrate Ottava with Ethicon instruments, imaging systems, and AI algorithms to create a unified digital surgical ecosystem.

Tim Schmid also mentioned in the interview: "The competition in the future will not be about who has more robots, but who can use data to make robots smarter." This concept is driving Johnson & Johnson to build long-term competitive advantages.

Financial Reports andTim Schmid'sThe interviews collectively convey a signal: Johnson & Johnson's transformation is entering the results delivery phase.

Its operating structure is more focused on high-margin, high-growth areas, and the quality of profitability continues to improve.

The company expects,By 2026, the revenue share of the MedTech sector will increase from the current 35% to over 40%, while the compound annual growth rate of digital surgery and cardiovascular businesses is expected to exceed 10%.

At the same time, Johnson & Johnson maintains a robust financial structure: a debt ratio of only about 22%, a credit rating maintained at AA, and shareholder dividend payouts exceeding $13 billion over the past 12 months, demonstrating strong cash generation capabilities.

Of course, risks still exist. The surgical robot market is highly competitive, with companies like Intuitive Surgical and Medtronic having already established deep roots in the surgical robotics field; factors such as drug patent expirations and regulatory approval delays could also lead to short-term fluctuations.

But overall, Johnson & Johnson has completed a strategic transformation from "solid defense" to "active offense" by divesting low-growth businesses, strengthening high-tech assets, and intensifying AI and data-driven innovation.

In the future, Johnson & Johnson will no longer be just a pharmaceutical company, but an intelligent healthcare platform that integrates drugs, devices, data, and algorithms. The numbers in the financial reports are merely outcomes; behind them reflects a century-old enterprise’s self-reinvention amidst the technological wave.

When data and AI become the new language of healthcare, Johnson & Johnson may be writing the starting point of its next century.

‍

‍